E
44.81
1.03 (2.35%)
| Penutupan Terdahulu | 43.78 |
| Buka | 43.72 |
| Jumlah Dagangan | 1,979,341 |
| Purata Dagangan (3B) | 2,619,606 |
| Modal Pasaran | 12,062,965,760 |
| Harga / Pendapatan (P/E TTM) | 18.83 |
| Harga / Pendapatan (P/E Ke hadapan) | 15.15 |
| Harga / Jualan (P/S) | 5.48 |
| Harga / Buku (P/B) | 5.43 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Feb 2026 |
| Margin Keuntungan | 27.99% |
| Margin Operasi (TTM) | 33.64% |
| EPS Cair (TTM) | 2.19 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 30.60% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 327.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 8.78% |
| Nisbah Semasa (MRQ) | 3.50 |
| Aliran Tunai Operasi (OCF TTM) | 842.59 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 559.13 M |
| Pulangan Atas Aset (ROA TTM) | 18.05% |
| Pulangan Atas Ekuiti (ROE TTM) | 30.22% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Exelixis, Inc. | Menaik | Menaik |
AISkor Stockmoo
0.5
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | 3.0 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -3.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.50 |
|
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 2.20% |
| % Dimiliki oleh Institusi | 93.99% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 52.00 (HC Wainwright & Co., 16.05%) | Beli |
| Median | 48.00 (7.12%) | |
| Rendah | 40.00 (UBS, -10.73%) | Pegang |
| Purata | 46.40 (3.55%) | |
| Jumlah | 2 Beli, 3 Pegang | |
| Harga Purata @ Panggilan | 41.97 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 08 Jan 2026 | 52.00 (16.05%) | Beli | 44.15 |
| 05 Nov 2025 | 49.00 (9.35%) | Beli | 40.37 | |
| Morgan Stanley | 08 Jan 2026 | 48.00 (7.12%) | Pegang | 44.15 |
| 05 Nov 2025 | 45.00 (0.42%) | Beli | 40.37 | |
| UBS | 06 Nov 2025 | 40.00 (-10.73%) | Pegang | 40.80 |
| Barclays | 05 Nov 2025 | 41.00 (-8.50%) | Pegang | 40.37 |
| TD Cowen | 05 Nov 2025 | 51.00 (13.81%) | Beli | 40.37 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| AFTAB DANA | 45.44 | 45.44 | 92,324 | 4,195,203 |
| HALEY PATRICK J. | 45.44 | 45.44 | 107,176 | 4,870,077 |
| MORRISSEY MICHAEL | 45.44 | 45.44 | 408,549 | 18,564,467 |
| SENNER CHRISTOPHER J. | 45.44 | 45.44 | 109,015 | 4,953,642 |
| Jumlah Keseluruhan Kuantiti Bersih | 717,064 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 32,583,388 | |||
| Purata Pembelian Keseluruhan ($) | 45.44 | |||
| Purata Jualan Keseluruhan ($) | 45.44 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| SENNER CHRISTOPHER J. | Pegawai | 15 Jan 2026 | Diperolehi (+) | 149,474 | 45.44 | 6,792,099 |
| SENNER CHRISTOPHER J. | Pegawai | 15 Jan 2026 | Dibuang (-) | 40,459 | 45.44 | 1,838,457 |
| HALEY PATRICK J. | Pegawai | 15 Jan 2026 | Diperolehi (+) | 139,508 | 45.44 | 6,339,244 |
| HALEY PATRICK J. | Pegawai | 15 Jan 2026 | Dibuang (-) | 32,332 | 45.44 | 1,469,166 |
| AFTAB DANA | Pegawai | 15 Jan 2026 | Diperolehi (+) | 119,578 | 45.44 | 5,433,624 |
| AFTAB DANA | Pegawai | 15 Jan 2026 | Dibuang (-) | 27,254 | 45.44 | 1,238,422 |
| MORRISSEY MICHAEL | Pegawai | 15 Jan 2026 | Diperolehi (+) | 548,073 | 45.44 | 24,904,437 |
| MORRISSEY MICHAEL | Pegawai | 15 Jan 2026 | Dibuang (-) | 139,524 | 45.44 | 6,339,971 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 11 Jan 2026 | Pengumuman | Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026 |
| 07 Jan 2026 | Pengumuman | Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer |
| 06 Jan 2026 | Pengumuman | Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026 |
| 03 Dec 2025 | Pengumuman | Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025 |
| 06 Nov 2025 | Pengumuman | Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November |
| 04 Nov 2025 | Pengumuman | Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |